Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?
作者信息
Mazzeffi Michael, Chow Jonathan H, Amoroso Anthony, Tanaka Kenichi
机构信息
From the Department of Anesthesiology.
Division of Infectious Disease, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
出版信息
Anesth Analg. 2020 Sep;131(3):690-693. doi: 10.1213/ANE.0000000000005059.
Abstract
摘要
相似文献
1
Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?
Anesth Analg. 2020 Sep;131(3):690-693. doi: 10.1213/ANE.0000000000005059.
2
COVID-19 update: Covid-19-associated coagulopathy.
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
3
2020 - Year of COVID-19.
J Thromb Haemost. 2020 Sep;18(9):2081. doi: 10.1111/jth.15041.
4
A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic.
Thromb Res. 2020 Aug;192:73-74. doi: 10.1016/j.thromres.2020.05.024. Epub 2020 May 16.
5
COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).
Blood Transfus. 2020 May;18(3):167-169. doi: 10.2450/2020.0083-20. Epub 2020 Apr 8.
6
ISTH DIC subcommittee communication on anticoagulation in COVID-19.
J Thromb Haemost. 2020 Sep;18(9):2138-2144. doi: 10.1111/jth.15004.
7
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies.
Ann Hematol. 2020 Sep;99(9):1953-1965. doi: 10.1007/s00277-020-04182-4. Epub 2020 Jul 15.
8
Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study.
Circulation. 2020 Aug 11;142(6):611-614. doi: 10.1161/CIRCULATIONAHA.120.048925. Epub 2020 Jun 17.
9
Lessons from the Italian COVID-19 frontline.
Minerva Med. 2020 Aug;111(4):303-305. doi: 10.23736/S0026-4806.20.06664-1.
10
Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients.
Curr Probl Cardiol. 2020 Sep;45(9):100648. doi: 10.1016/j.cpcardiol.2020.100648. Epub 2020 Jun 27.
引用本文的文献
1
Protein C Pretreatment Protects Endothelial Cells from SARS-CoV-2-Induced Activation.
Viruses. 2024 Jun 28;16(7):1049. doi: 10.3390/v16071049.
2
Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221077096. doi: 10.1177/10760296221077096.
3
Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
Int Immunopharmacol. 2022 Mar;104:108516. doi: 10.1016/j.intimp.2021.108516. Epub 2022 Jan 6.
4
The Association of Low Vitamin K Status with Mortality in a Cohort of 138 Hospitalized Patients with COVID-19.
Nutrients. 2021 Jun 9;13(6):1985. doi: 10.3390/nu13061985.
5
Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19.
Thromb Res. 2021 Aug;204:13-15. doi: 10.1016/j.thromres.2021.05.016. Epub 2021 May 29.
6
How we approach thrombosis risk in children with COVID-19 infection and MIS-C.
Pediatr Blood Cancer. 2021 Jul;68(7):e29049. doi: 10.1002/pbc.29049. Epub 2021 May 6.
7
Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs.
J Immunol Res. 2020 Dec 19;2020:8827670. doi: 10.1155/2020/8827670. eCollection 2020.
本文引用的文献
1
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
2
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.
3
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.
N Engl J Med. 2020 May 14;382(20):e60. doi: 10.1056/NEJMc2009787. Epub 2020 Apr 28.
4
Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.
J Thromb Haemost. 2020 Jul;18(7):1738-1742. doi: 10.1111/jth.14850. Epub 2020 Jun 24.
5
ST-Segment Elevation in Patients with Covid-19 - A Case Series.
N Engl J Med. 2020 Jun 18;382(25):2478-2480. doi: 10.1056/NEJMc2009020. Epub 2020 Apr 17.
6
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
7
Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: A systematic review and meta-analysis.
J Thromb Haemost. 2020 Jul;18(7):1618-1625. doi: 10.1111/jth.14812. Epub 2020 Apr 27.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
JAMA. 2019 May 28;321(20):1993-2002. doi: 10.1001/jama.2019.5358.
10
PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.
Blood. 2018 Mar 15;131(11):1163-1171. doi: 10.1182/blood-2017-10-810895. Epub 2018 Jan 17.
Zotero 插件